Link: https://links.sgx.com/1.0.0/corporate-announcements/0F6RXVDL9962PW1W/a25183b6686c1c9548efe9a1c1c41788009f6f6cbeee86f556710150fea27333

Summary: Takeda's 2025 CEO Shareholder Letter announces the CEO's retirement in June 2026 and names Julie Kim as the incoming President and CEO. The letter discusses Takeda's progress, its strong business performance, and advancements in its pipeline, alongside digital transformation initiatives. It also outlines the company's perspective on the healthcare environment, advocating for pragmatic reforms like increased spending, insurance, preventative care, and pricing transparency, while emphasizing innovation and regulatory oversight for the biopharmaceutical industry. The letter reflects on Takeda's transformation into a global biopharmaceutical leader and its commitment to building resilient health systems and supporting its people.